FDA Grants RMAT Designation to BridgeBio’s Investigational Gene Therapy BBP-812 for Canavan Disease

- Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements...

September 11, 2024 | Wednesday | News
Sun Pharma and Moebius Medical Receive FDA Fast Track Designation for Osteoarthritis Treatment MM-II

Sun Pharma and Israel-based Moebius Medical Limited announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) t...

September 09, 2024 | Monday | News
FDA Grants Full Approval for FILSPARI in Treating IgA Nephropathy, Marking Major Advancement in Kidney Disease Care

FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data sh...

September 06, 2024 | Friday | News
U.S. FDA Grants Emergency Use Authorization for Updated Novavax COVID-19 Vaccine Targeting Current Variants

– The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for an updated version of the Novavax COVID-19 Vaccine,...

September 04, 2024 | Wednesday | News
Novavax Prepares to Launch Protein-Based COVID-19 Vaccine in Thousands of U.S. Locations with Pre-Filled Syringes

Novavax expects pre-filled syringes will be broadly available in thousands of locations across the U.S. Novavax's vaccine is the only protein-based op...

September 02, 2024 | Monday | News
Emergent BioSolutions Secures FDA Approval to Expand ACAM2000® Vaccine Indication for Mpox Prevention Amid Global Health Emergency

Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (s...

August 30, 2024 | Friday | News
Novartis’ Leqvio® (inclisiran) Outperforms Placebo and Ezetimibe in Phase III V-MONO Study for LDL-C Reduction

Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C r...

August 29, 2024 | Thursday | News
AC Immune's Partner LMI Receives FDA Fast Track Designation for PI-2620 in Alzheimer's and Other Neurodegenerative Diseases

  PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI This Fast Track designation applies across Al...

August 28, 2024 | Wednesday | News
BeiGene's Investigational BTK Degrader BGB-16673 Receives FDA Fast Track Designation for Relapsed CLL/SLL

BeiGene, a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BGB-16673, an ...

August 27, 2024 | Tuesday | News
Pfizer and BioNTech Launch KP.2-Adapted COVID-19 Vaccine for 2024-2025 Season

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of...

August 23, 2024 | Friday | News
Sibel Health Expands Capabilities with New FDA Clearances for ANNE® Wearable Sensors

Sibel Health announces two additional FDA-clearances enabling its advanced wearable sensors to operate with compatible third party software applications. I...

August 23, 2024 | Friday | News
FDA Accepts Application for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Acceptance based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo (nivolumab) plus Yervoy(ipilimumab) compared to in...

August 22, 2024 | Thursday | News
Phanes Therapeutics Secures FDA Orphan Drug Designation for PT217 in Treating Neuroendocrine Carcinoma

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today th...

August 19, 2024 | Monday | News
Lykos Therapeutics Restructures to Focus on Resubmission of NDA for PTSD Treatment Midomafetamine

Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, today announced a reorganization to best support the company as...

August 16, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close